Waleed H.  Hassanein net worth and biography

Waleed Hassanein Biography and Net Worth

Waleed H. Hassanein, M.D., age 52, our founder, has served as our President and Chief Executive Officer and as a member of our Board since August 1998. Prior to founding TransMedics, Inc. Dr. Hassanein completed a three-year cardiac surgery research fellowship at West Roxbury VA Medical Center and Brigham and Women’s Hospital, a Harvard Medical School affiliate. Prior to his research fellowship, Dr. Hassanein completed two years Provided by Tagnifi.

What is Waleed H. Hassanein's net worth?

The estimated net worth of Waleed H. Hassanein is at least $4.23 million as of October 15th, 2024. Dr. Hassanein owns 61,643 shares of TransMedics Group stock worth more than $4,227,477 as of March 29th. This net worth approximation does not reflect any other assets that Dr. Hassanein may own. Additionally, Dr. Hassanein receives an annual salary of $1,820,000.00 as CEO at TransMedics Group. Learn More about Waleed H. Hassanein's net worth.

How old is Waleed H. Hassanein?

Dr. Hassanein is currently 56 years old. There are 3 older executives and no younger executives at TransMedics Group. Learn More on Waleed H. Hassanein's age.

What is Waleed H. Hassanein's salary?

As the CEO of TransMedics Group, Inc., Dr. Hassanein earns $1,820,000.00 per year. Learn More on Waleed H. Hassanein's salary.

How do I contact Waleed H. Hassanein?

The corporate mailing address for Dr. Hassanein and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at investors@transmedics.com. Learn More on Waleed H. Hassanein's contact information.

Has Waleed H. Hassanein been buying or selling shares of TransMedics Group?

Waleed H. Hassanein has not been actively trading shares of TransMedics Group within the last three months. Most recently, Waleed H. Hassanein sold 8,625 shares of the business's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a transaction totalling $1,144,623.75. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at $8,180,642.53. Learn More on Waleed H. Hassanein's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), and Anil Ranganath (Insider). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, insiders at the sold shares 31 times. They sold a total of 371,868 shares worth more than $45,254,859.16. The most recent insider tranaction occured on December, 2nd when insider Tamer I Khayal sold 1,084 shares worth more than $93,657.60. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 12/2/2024.

Waleed H. Hassanein Insider Trading History at TransMedics Group

Waleed H. Hassanein Buying and Selling Activity at TransMedics Group

This chart shows Waleed H Hassanein's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M-$5M$0$5M$10MTotal Insider BuyingTotal Insider Selling

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $68.58
Low: $67.75
High: $70.42

50 Day Range

MA: $69.11
Low: $56.73
High: $79.42

2 Week Range

Now: $68.58
Low: $55.00
High: $177.37

Volume

612,338 shs

Average Volume

1,322,479 shs

Market Capitalization

$2.31 billion

P/E Ratio

72.96

Dividend Yield

N/A

Beta

2.12